Glasziou P P, Simes R J, Gelber R D
Department of Public Health, University of Sydney, Australia.
Stat Med. 1990 Nov;9(11):1259-76. doi: 10.1002/sim.4780091106.
We present a technique, quality adjusted survival analysis, for the analysis of controlled trials where patients may experience several health states which differ in their quality of life. When the data are censored, a survival analysis of the quality adjusted life years achieved may involve informative censoring, and produce biased estimates. To overcome this, we partition the survival curve; the resulting areas, which represent the mean time in each state, are multiplied by utility weights to provide an unbiased estimate of (restricted) quality adjusted survival. If the appropriate weights are in doubt, the results are best presented as a threshold analysis over the utility weights, allowing individual recommendation to be read from a simple graph. The certainty of the conclusions can be presented as confidence bands on the threshold line. The techniques are illustrated with a re-analysis of a large three-arm trial of adjuvant chemoendocrine therapy for stage II breast cancer in postmenopausal women. This shows that if the value of time spent in toxicity is greater than the time spent in relapse, we can be 95 per cent confident that chemoendocrine therapy is the preferred option.
我们提出了一种技术,即质量调整生存分析,用于分析对照试验,这类试验中的患者可能会经历几种生活质量不同的健康状态。当数据出现删失时,对所获得的质量调整生命年进行生存分析可能会涉及信息删失,并产生有偏差的估计。为克服这一问题,我们将生存曲线进行划分;所得代表各状态平均时间的面积,乘以效用权重,以提供(受限的)质量调整生存的无偏估计。如果对适当的权重存疑,最好将结果呈现为对效用权重的阈值分析,这样可从简单图表中读取个体推荐。结论的确定性可表示为阈值线上的置信带。通过对一项针对绝经后女性II期乳腺癌辅助化学内分泌治疗的大型三臂试验进行重新分析,对这些技术进行了说明。这表明,如果在毒性状态下所花费时间的价值大于复发所花费的时间,我们有95%的把握确信化学内分泌治疗是首选方案。